Mesoblast (ASX:MSB) was the top performer for the year up 835% (as of December 30). On December 18 Mesoblast announced that the US Food and Drug Administration (FDA) had finally approved its therapy ...

UK titanium dioxide manufacturer Venator (Stockton-on-Tees; www.venatorcorp.com) is still headed downhill after reporting further declines in sales volumes ahead of the official presentation of the ...